Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522545 · ClinicalTrials.gov registry record · Phase 1
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
A Phase 1 study of Treatment-resistant Bipolar Depression, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03522545 is a Phase 1 study of Treatment-resistant Bipolar Depression that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03522545, a Phase 1 study of Treatment-resistant Bipolar Depression, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522545
The ClinicalTrials.gov registry entry for NCT03522545 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-resistant Bipolar Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03522545 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03522545 about?
NCT03522545 is a clinical study titled "Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression". The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
What is the current status of trial NCT03522545?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-04-20. Estimated completion is 2026-12-01.
What conditions does trial NCT03522545 study?
This clinical trial studies the following conditions: Treatment-resistant Bipolar Depression.
What interventions are being tested in trial NCT03522545?
The interventions under investigation include: Placebo (BIOLOGICAL), Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03522545?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03522545 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-resistant Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.